Autoimmune Disorders Medications

Topics under Autoimmune Disorders

• Autoimmune Hepatitis (4 drugs in 2 topics)

• Celiac Disease (1 drug)

• Cogan's Syndrome (10 drugs)

• Schnitzler Syndrome (1 drug)

Learn more about Autoimmune Disorders

Micromedex Care Notes:

• Autoimmune Thyroid Disorders

Medical Encyclopedia:

• Autoimmune disorders

Drug List:

Daktarin Oral

Daktarin Oral may be available in the countries listed below.

Ingredient matches for Daktarin Oral

Miconazole

Miconazole is reported as an ingredient of Daktarin Oral in the following countries:

• Spain

International Drug Name Search

Spironolacton AccordHealthcare

Spironolacton AccordHealthcare may be available in the countries listed below.

Ingredient matches for Spironolacton AccordHealthcare

Spironolactone

Spironolactone is reported as an ingredient of Spironolacton AccordHealthcare in the following countries:

• Netherlands

International Drug Name Search

Doctiverine

Doctiverine may be available in the countries listed below.

Ingredient matches for Doctiverine

Simvastatin

Simvastatin is reported as an ingredient of Doctiverine in the following countries:

• Greece

International Drug Name Search

Sefirom

Sefirom may be available in the countries listed below.

Ingredient matches for Sefirom

Ceftriaxone

Ceftriaxone disodium salt (a derivative of Ceftriaxone) is reported as an ingredient of Sefirom in the following countries:

• Japan

International Drug Name Search

N-Lactase

N-Lactase may be available in the countries listed below.

Ingredient matches for N-Lactase

Tilactase

Tilactase is reported as an ingredient of N-Lactase in the following countries:

• Japan

International Drug Name Search

Softear

Softear may be available in the countries listed below.

Ingredient matches for Softear

Cyanocobalamin

Cyanocobalamin is reported as an ingredient of Softear in the following countries:

• Japan

International Drug Name Search

Novocortil

Novocortil may be available in the countries listed below.

Ingredient matches for Novocortil

Hydrocortisone

Hydrocortisone is reported as an ingredient of Novocortil in the following countries:

• Peru

International Drug Name Search

Sulfadiazina L. CH

Sulfadiazina L.CH. may be available in the countries listed below.

Ingredient matches for Sulfadiazina L.CH.

Sulfadiazine

Sulfadiazine is reported as an ingredient of Sulfadiazina L.CH. in the following countries:

• Chile

International Drug Name Search

Zerpyco

Zerpyco may be available in the countries listed below.

Ingredient matches for Zerpyco

Pinaverium Bromide

Pinaverium Bromide is reported as an ingredient of Zerpyco in the following countries:

• Mexico

International Drug Name Search

Thalomid

Thalomid is a brand name of thalidomide, approved by the FDA in the following formulation(s):

THALOMID (thalidomide - capsule; oral)

• 
  Manufacturer: CELGENE
  
  Approval date: July 16, 1998
  
  Strength(s): 50MG
  


• 
  Manufacturer: CELGENE
  
  Approval date: January 17, 2003
  
  Strength(s): 100MG, 200MG ^[RLD]


• 
  Manufacturer: CELGENE
  
  Approval date: January 10, 2007
  
  Strength(s): 150MG
  

Has a generic version of Thalomid been approved?

No. There is currently no therapeutically equivalent version of Thalomid available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Thalomid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods and compositions for inhibition of angiogenesis
  Patent 5,629,327
  Issued: May 13, 1997
  Inventor(s): D'Amato; Robert
  Assignee(s): Childrens Hospital Medical Center Corp.
  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
  
  Patent expiration dates:
  
  
  • May 13, 2014
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  



• 
  Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
  Patent 6,045,501
  Issued: April 4, 2000
  Inventor(s): Elsayed; Marc & Williams; Bruce
  Assignee(s): Celgene Corporation
  Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
  
  Patent expiration dates:
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  



• 
  Methods and compositions for inhibition of angiogenesis by thalidomide
  Patent 6,235,756
  Issued: May 22, 2001
  Inventor(s): D'Amato; Robert
  Assignee(s): The Children's Medical Center Corporation
  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
  
  Patent expiration dates:
  
  
  • March 1, 2013
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  



• 
  Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
  Patent 6,315,720
  Issued: November 13, 2001
  Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
  Assignee(s): Celgene Corporation
  Improved methods for delivering to a patient in need of the drug, while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug are disclosed. The methods are of the type in which prescriptions for the drug are filled only after a computer readable storage medium has been consulted to assure that the prescriber, pharmacy and patient have been properly registered in the medium before the patient is approved to receive the drug. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to the side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
  
  Patent expiration dates:
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
  
  



• 
  Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
  Patent 6,561,976
  Issued: May 13, 2003
  Inventor(s): Marc; Elsayed & Bruce; Williams
  Assignee(s): Celgene Corporation
  Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
  
  Patent expiration dates:
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  



• 
  Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
  Patent 6,561,977
  Issued: May 13, 2003
  Inventor(s): Bruce A.; Williams & Joseph K.; Kaminski
  Assignee(s): Celgene Corporation
  Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
  
  Patent expiration dates:
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  



• 
  Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
  Patent 6,755,784
  Issued: June 29, 2004
  Inventor(s): Bruce A.; Williams & Joseph K.; Kaminski
  Assignee(s): Celgene Corporation
  Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
  
  Patent expiration dates:
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  



• 
  Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
  Patent 6,869,399
  Issued: March 22, 2005
  Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
  Assignee(s): Celgene Corporation
  Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
  
  Patent expiration dates:
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  



• 
  Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
  Patent 6,908,432
  Issued: June 21, 2005
  Inventor(s): Elsayed; Marc & Williams; Bruce
  Assignee(s): Celgene Corporation
  Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
  
  Patent expiration dates:
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  



• 
  Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
  Patent 7,141,018
  Issued: November 28, 2006
  Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
  Assignee(s): Celgene Corporation
  Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
  
  Patent expiration dates:
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  



• 
  Pharmaceutical compositions and dosage forms of thalidomide
  Patent 7,230,012
  Issued: June 12, 2007
  Inventor(s): D'Angio; Paul & McCarty; John
  Assignee(s): Celgene Corporation
  Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
  
  Patent expiration dates:
  
  
  • December 9, 2023
    
    ✓ 
    Drug product
  
  



• 
  Methods and compositions for inhibition of angiogenesis
  Patent 7,435,745
  Issued: October 14, 2008
  Inventor(s): D'Amato; Robert J.
  Assignee(s): Celgene Corporation
  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
  
  Patent expiration dates:
  
  
  • November 3, 2017
    
    ✓ 
    Patent use: USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  



• 
  Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide
  Patent 7,723,361
  Issued: May 25, 2010
  Inventor(s): D'Amato; Robert
  Assignee(s): Celgene Corporation
  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
  
  Patent expiration dates:
  
  
  • March 1, 2013
    
    ✓ 
    Patent use: USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  
  



• 
  Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
  Patent 7,874,984
  Issued: January 25, 2011
  Inventor(s): Elsayed; Marc & Williams; Bruce
  Assignee(s): Celgene Corporation
  Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
  
  Patent expiration dates:
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
  
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
  
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
  
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  
  
  • August 28, 2018
    
    ✓ 
    Patent use: TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
  
  



• 
  Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
  Patent 7,959,566
  Issued: June 14, 2011
  Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
  Assignee(s): Celgene Corporation
  Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
  
  Patent expiration dates:
  
  
  • October 23, 2020
    
    ✓ 
    Patent use: USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 23, 2013 - ORPHAN DRUG EXCLUSIVITY
  
  
  • May 25, 2013 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Thalomid Consumer Information (Drugs.com)
• Thalomid Consumer Information (Wolters Kluwer)
• Thalomid Consumer Information (Cerner Multum)
• Thalomid Advanced Consumer Information (Micromedex)
• Thalomid AHFS DI Monographs (ASHP)
• Thalidomide Consumer Information (Wolters Kluwer)
• Thalidomide Consumer Information (Cerner Multum)
• Thalidomide Advanced Consumer Information (Micromedex)
• Thalidomide AHFS DI Monographs (ASHP)

Zopiclon-Teva

Zopiclon-Teva may be available in the countries listed below.

Ingredient matches for Zopiclon-Teva

Eszopiclone

Zopiclone is reported as an ingredient of Zopiclon-Teva in the following countries:

• Germany

International Drug Name Search

Supacal

Supacal may be available in the countries listed below.

Ingredient matches for Supacal

Trepibutone

Trepibutone is reported as an ingredient of Supacal in the following countries:

• Japan

International Drug Name Search

Dermosavit

Dermosavit may be available in the countries listed below.

Ingredient matches for Dermosavit

Retinol

Retinol palmitate (a derivative of Retinol) is reported as an ingredient of Dermosavit in the following countries:

• Poland

International Drug Name Search

Ultane

In the US, Ultane (sevoflurane systemic) is a member of the drug class general anesthetics and is used to treat Anesthesia.

US matches:

• Ultane


• Ultane Amerinet


• Ultane Novation

Ingredient matches for Ultane

Sevoflurane

Sevoflurane is reported as an ingredient of Ultane in the following countries:

• South Africa


• Taiwan


• United States

International Drug Name Search

Doxycyclin Axapharm

Doxycyclin Axapharm may be available in the countries listed below.

Ingredient matches for Doxycyclin Axapharm

Doxycycline

Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Doxycyclin Axapharm in the following countries:

• Switzerland

International Drug Name Search

Vita Fizz C

Vita Fizz C may be available in the countries listed below.

Ingredient matches for Vita Fizz C

Ascorbic Acid

Ascorbic Acid is reported as an ingredient of Vita Fizz C in the following countries:

• Argentina

International Drug Name Search

Osteomalacia Medications

Definition of Osteomalacia: Osteomalacia involves softening of the bones caused by a deficiency of vitamin D or problems with the metabolism of this vitamin.

Drugs associated with Osteomalacia

The following drugs and medications are in some way related to, or used in the treatment of Osteomalacia. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Osteomalacia

Medical Encyclopedia:

• Osteomalacia

Drug List:

Calcidol

Calciferol-Solution

Calciquid

Drisdol

Neo-Calglucon

Posture

Ridactate

Vitamin-D2

Tyzeka

Tyzeka is a brand name of telbivudine, approved by the FDA in the following formulation(s):

TYZEKA (telbivudine - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: October 25, 2006
  
  Strength(s): 600MG ^[RLD]

Has a generic version of Tyzeka been approved?

No. There is currently no therapeutically equivalent version of Tyzeka available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tyzeka. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  &bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B
  Patent 6,395,716
  Issued: May 28, 2002
  Inventor(s): Gilles; Gosselin & Jean-Louis; Imbach & Martin L.; Bryant
  Assignee(s): Novirio Pharmaceuticals Limited
  Centre National da la Recherche Scientifique
  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
  
  Patent expiration dates:
  
  
  • August 10, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
  
  
  
  • August 10, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
  
  



• 
  &bgr;-L-2'-deoxy-nucleosides for the treatment of hepatitis B
  Patent 6,444,652
  Issued: September 3, 2002
  Inventor(s): Gilles; Gosselin & Jean-Louis; Imbach & Martin L.; Bryant
  Assignee(s): Novirio Pharmaceuticals Limited
  Centre National da la Recherche Scientifique
  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
  
  Patent expiration dates:
  
  
  • August 10, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
  
  
  
  • August 10, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
  
  



• 
  &bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B
  Patent 6,566,344
  Issued: May 20, 2003
  Inventor(s): Gilles; Gosselin & Jean-Louis; Imbach & Martin L.; Bryant
  Assignee(s): Idenix Pharmaceuticals, Inc.
  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentoftiranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
  
  Patent expiration dates:
  
  
  • August 10, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
  
  
  
  • August 10, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
  
  



• 
  &bgr;-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B
  Patent 6,569,837
  Issued: May 27, 2003
  Inventor(s): Gilles; Gosselin & Jean-Louis; Imbach & Martin L.; Bryant
  Assignee(s): Idenix Pharmaceuticals Inc.
  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
  
  Patent expiration dates:
  
  
  • October 25, 2020
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
  
  
  
  • October 25, 2020
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
  
  



• 
  Crystalline and amorphous forms of beta-L-2′-deoxythymidine
  Patent 7,589,079
  Issued: September 15, 2009
  Inventor(s): Jonaitis; David & Storer; Richard
  Assignee(s): Novartis AG
  Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2′-deoxythymidine can be used in the manufacture of other forms of beta-L-2′-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.
  
  Patent expiration dates:
  
  
  • September 11, 2023
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
  Patent 7,795,238
  Issued: September 14, 2010
  Inventor(s): Gosselin; Gilles & Imbach; Jean-Louis & Bryant; Martin L.
  Assignee(s): Idenix Pharmaceuticals, Inc.
  Centre National de la Recherche Scientifique
  L'Université Montpellier II
  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
  
  Patent expiration dates:
  
  
  • August 10, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
  
  



• 
  Crystalline and amorphous forms of beta-L-2′-deoxythymidine
  Patent 7,858,594
  Issued: December 28, 2010
  Inventor(s): Jonaitis; David & Storer; Richard
  Assignee(s): Novartis Pharma AG
  Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2′-deoxythymidine can be used in the manufacture of other forms of beta-L-2′-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.
  
  Patent expiration dates:
  
  
  • September 11, 2023
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 25, 2011 - NEW CHEMICAL ENTITY
  
  

See also...

• Tyzeka Consumer Information (Drugs.com)
• Tyzeka Consumer Information (Wolters Kluwer)
• Tyzeka Consumer Information (Cerner Multum)
• Tyzeka Advanced Consumer Information (Micromedex)
• Tyzeka AHFS DI Monographs (ASHP)
• Telbivudine Consumer Information (Wolters Kluwer)
• Telbivudine Consumer Information (Cerner Multum)
• Telbivudine Advanced Consumer Information (Micromedex)
• Telbivudine AHFS DI Monographs (ASHP)

Z-Thro

Z-Thro may be available in the countries listed below.

Ingredient matches for Z-Thro

Roxithromycin

Roxithromycin is reported as an ingredient of Z-Thro in the following countries:

• India

International Drug Name Search

Sulpivert

Sulpivert may be available in the countries listed below.

Ingredient matches for Sulpivert

Sulpiride

Sulpiride is reported as an ingredient of Sulpivert in the following countries:

• Germany

International Drug Name Search

Vitascorbol

Vitascorbol may be available in the countries listed below.

Ingredient matches for Vitascorbol

Ascorbic Acid

Ascorbic Acid is reported as an ingredient of Vitascorbol in the following countries:

• France


• Tunisia

International Drug Name Search

Siamformet

Siamformet may be available in the countries listed below.

Ingredient matches for Siamformet

Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Siamformet in the following countries:

• Thailand

International Drug Name Search

Pradaxa

Pradaxa is a brand name of dabigatran, approved by the FDA in the following formulation(s):

PRADAXA (dabigatran etexilate mesylate - capsule; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: October 18, 2010
  
  Strength(s): 150MG ^[RLD], 75MG
  

Has a generic version of Pradaxa been approved?

No. There is currently no therapeutically equivalent version of Pradaxa available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pradaxa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
  Patent 6,087,380
  Issued: July 11, 2000
  Inventor(s): Hauel; Norbert & Priepke; Henning & Ries; Uwe & Stassen; Jean Marie & Wienen; Wolfgang
  Assignee(s): Boehringer Ingelheim Pharma KG
  New disubstituted bicyclic heterocycles of general formula EQU R.sub.a --A--Het--B--Ar--E (I) Compounds of the above general formula I, wherein E denotes an R.sub.b NH--C(.dbd.NH)-- group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E denotes a cyano group, are valuable intermediates for preparing the other compounds of general formula I. Exemplary compounds of formula I are: (a) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide, (b) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, (c) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl- carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, and (d) 1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]-benzimid azol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl) amide.
  
  Patent expiration dates:
  
  
  • February 18, 2018
    
    ✓ 
    Patent use: INHIBITION OF THROMBIN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Film container
  Patent 7,866,474
  Issued: January 11, 2011
  Inventor(s): Geser; Johannes & Beyer; Sebastian
  Assignee(s): Boehringer Ingelheim International GmbH
  A film container (FIG. 4) comprises two rectangular films (5) joined together at their periphery to form a receiving chamber (6) for a filling (7), particularly a pharmaceutical formulation of an active substance, at least one of said films (5) being provided, for the purpose of tearing it open, with a marking (13) formed within the connecting region, which is exposed after the films (5) have been bent. The marking (13) extends centrally between two opposing outer edges (11) of the film container (1).
  
  Patent expiration dates:
  
  
  • August 31, 2027
    
    ✓ 
    Drug product
  
  



• 
  3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
  Patent 7,932,273
  Issued: April 26, 2011
  Inventor(s): Schmid; Rolf & Sieger; Peter & Sobotta; Rainer
  Assignee(s): Boehringer Ingelheim International GmbH
  Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition.
  
  Patent expiration dates:
  
  
  • September 7, 2025
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 19, 2015 - NEW CHEMICAL ENTITY
  
  

See also...

• Pradaxa Consumer Information (Drugs.com)
• Pradaxa Consumer Information (Wolters Kluwer)
• Pradaxa Consumer Information (Cerner Multum)
• Pradaxa Advanced Consumer Information (Micromedex)
• Dabigatran Consumer Information (Wolters Kluwer)
• Dabigatran Consumer Information (Cerner Multum)
• Dabigatran Advanced Consumer Information (Micromedex)

Nor-Fluozol

Nor-Fluozol may be available in the countries listed below.

Ingredient matches for Nor-Fluozol

Fluconazole

Fluconazole is reported as an ingredient of Nor-Fluozol in the following countries:

• Dominican Republic


• El Salvador


• Guatemala


• Honduras


• Nicaragua

International Drug Name Search

Soleton

Soleton may be available in the countries listed below.

Ingredient matches for Soleton

Zaltoprofen

Zaltoprofen is reported as an ingredient of Soleton in the following countries:

• Japan


• Mexico

International Drug Name Search

Xopenex

See also: Generic Xopenex HFA

Xopenex is a brand name of levalbuterol, approved by the FDA in the following formulation(s):

XOPENEX (levalbuterol hydrochloride - solution; inhalation)

• 
  Manufacturer: SUNOVION
  
  Approval date: March 25, 1999
  
  Strength(s): EQ 0.021% BASE ^[RLD][AN], EQ 0.042% BASE ^[RLD][AN]


• 
  Manufacturer: SUNOVION
  
  Approval date: January 30, 2002
  
  Strength(s): EQ 0.0103% BASE ^[RLD][AN]


• 
  Manufacturer: SUNOVION
  
  Approval date: July 18, 2003
  
  Strength(s): EQ 0.25% BASE ^[RLD][AN]

Has a generic version of Xopenex been approved?

A generic version of Xopenex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Xopenex and have been approved by the FDA:

levalbuterol hydrochloride solution; inhalation

• 
  Manufacturer: DEY
  
  Approval date: March 20, 2009
  
  Strength(s): EQ 0.25% BASE ^[AN]


• 
  Manufacturer: WATSON LABS INC
  
  Approval date: April 9, 2008
  
  Strength(s): EQ 0.0103% BASE ^[AN], EQ 0.021% BASE ^[AN], EQ 0.042% BASE ^[AN]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xopenex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for treating asthma using optically pure (R)-albuterol
  Patent 5,362,755
  Issued: November 8, 1994
  Inventor(s): Barberich; Timothy J. & Young; James W.
  Assignee(s): Sepracor, Inc.
  The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with chronic administration of racemic albuterol.
  
  Patent expiration dates:
  
  
  • March 25, 2013
    
    ✓ 
    Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM
  
  



• 
  Method for treating asthma using optically pure R(-) albuterol
  Patent 5,547,994
  Issued: August 20, 1996
  Inventor(s): Barberich; Timothy J. & Young; James W.
  Assignee(s): Sepracor, Inc.
  The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
  
  Patent expiration dates:
  
  
  • August 20, 2013
    
    ✓ 
    Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM
  
  



• 
  Albuterol formulations
  Patent 6,451,289
  Issued: September 17, 2002
  Inventor(s): Robert J.; Wherry, III & Stewart H.; Mueller
  Assignee(s): Sepracor Inc.
  Albuterol formulations packaged in an oxygen-permeable plastic container have a long shelf life at room temperature. The formulations consist essentially of albuterol or a pharmaceutically acceptable salt thereof, sodium chloride, and water, have a pH of about 4, and contain less than 0.08% by weight of albuterol aldehyde and less than 1 ppm dissolved oxygen.
  
  Patent expiration dates:
  
  
  • March 21, 2021
    
  
  
  
  • March 21, 2021
    
    ✓ 
    Drug product
  
  

See also...

• Xopenex Consumer Information (Drugs.com)
• Xopenex Solution Consumer Information (Wolters Kluwer)
• Xopenex Consumer Information (Cerner Multum)
• Xopenex Advanced Consumer Information (Micromedex)
• Xopenex AHFS DI Monographs (ASHP)
• Levalbuterol Aerosol Consumer Information (Wolters Kluwer)
• Levalbuterol Solution Consumer Information (Wolters Kluwer)
• Levalbuterol Consumer Information (Cerner Multum)
• Xopenex Pediatric Advanced Consumer Information (Micromedex)
• Levalbuterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
• Levalbuterol AHFS DI Monographs (ASHP)

Diralon

Diralon may be available in the countries listed below.

Ingredient matches for Diralon

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diralon in the following countries:

• Venezuela

International Drug Name Search

Urinary Tract Stones Medications

Definition of Urinary Tract Stones: Bladder stones are hard buildups of mineral that form in the urinary bladder. A kidney stone is a solid mass made up of tiny crystals. One or more stones can be in the kidney or ureter at the same time. More...

Drugs associated with Urinary Tract Stones

The following drugs and medications are in some way related to, or used in the treatment of Urinary Tract Stones. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Urinary Tract Stones

• Calcium Oxalate Calculi with Hyperuricosuria (2 drugs)

• Nephrolithiasis (1 drug)

• Uric Acid Nephrolithiasis (0 drugs)

Learn more about Urinary Tract Stones

Medical Encyclopedia:

• Bladder stones
• Kidney stones
• Cystinuria

Drug List:

Bicitra

Cytra-2

Cytra-K-Powder-Pack

Flomax

Liqui-Dual-Citra

Mag-200

Mag-Caps

Mag-Ox

Mag-Ox-400

Maggel

Oracit

Poly-Citra-K-Crystals

Polycitra-K-Powder-Pack

Uro-Mag

Trandate

Trandate is a brand name of labetalol, approved by the FDA in the following formulation(s):

TRANDATE (labetalol hydrochloride - tablet; oral)

• 
  Manufacturer: PROMETHEUS LABS
  
  Approval date: August 1, 1984
  
  Strength(s): 200MG ^[RLD][AB]


• 
  Manufacturer: PROMETHEUS LABS
  
  Approval date: May 24, 1985
  
  Strength(s): 100MG ^[AB]

Has a generic version of Trandate been approved?

Yes. The following products are equivalent to Trandate:

labetalol hydrochloride tablet; oral

• 
  Manufacturer: IVAX SUB TEVA PHARMS
  
  Approval date: August 3, 1998
  
  Strength(s): 100MG ^[AB], 200MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: August 4, 1998
  
  Strength(s): 100MG ^[AB], 200MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: August 3, 1998
  
  Strength(s): 100MG ^[AB], 200MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trandate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Trandate.

See also...

• Trandate Consumer Information (Wolters Kluwer)
• Trandate Tablets Consumer Information (Wolters Kluwer)
• Trandate Consumer Information (Cerner Multum)
• Trandate Advanced Consumer Information (Micromedex)
• Trandate Intravenous Advanced Consumer Information (Micromedex)
• Labetalol Consumer Information (Wolters Kluwer)
• Labetalol Tablets Consumer Information (Wolters Kluwer)
• Labetalol Consumer Information (Cerner Multum)
• Labetalol Advanced Consumer Information (Micromedex)
• Labetalol Intravenous Advanced Consumer Information (Micromedex)
• Labetalol Hydrochloride AHFS DI Monographs (ASHP)

Glucovance

Glucovance is a brand name of glyburide/metformin, approved by the FDA in the following formulation(s):

GLUCOVANCE (glyburide; metformin hydrochloride - tablet; oral)

• 
  Manufacturer: BRISTOL MYERS SQUIBB
  
  Approval date: July 31, 2000
  
  Strength(s): 1.25MG;250MG ^[AB], 2.5MG;500MG ^[RLD][AB], 5MG;500MG ^[AB]

Has a generic version of Glucovance been approved?

A generic version of Glucovance has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Glucovance and have been approved by the FDA:

GLYBURIDE AND METFORMIN HYDROCHLORIDE (glyburide; metformin hydrochloride tablet; oral)

• 
  Manufacturer: ACTAVIS ELIZABETH
  
  Approval date: June 28, 2005
  
  Strength(s): 1.25MG;250MG ^[AB], 2.5MG;500MG ^[AB], 5MG;500MG ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: November 14, 2007
  
  Strength(s): 1.25MG;250MG ^[AB], 2.5MG;500MG ^[AB], 5MG;500MG ^[AB]


• 
  Manufacturer: COREPHARMA
  
  Approval date: November 19, 2004
  
  Strength(s): 1.25MG;250MG ^[AB], 2.5MG;500MG ^[AB], 5MG;500MG ^[AB]


• 
  Manufacturer: DR REDDYS LABS INC
  
  Approval date: June 3, 2009
  
  Strength(s): 1.25MG;250MG ^[AB], 2.5MG;500MG ^[AB], 5MG;500MG ^[AB]


• 
  Manufacturer: IVAX SUB TEVA PHARMS
  
  Approval date: February 18, 2004
  
  Strength(s): 1.25MG;250MG ^[AB], 2.5MG;500MG ^[AB], 5MG;500MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Glucovance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Solid oral dosage form comprising a combination of metformin and glibenclamide
  Patent 6,303,146
  Issued: October 16, 2001
  Inventor(s): Bonhomme; Yves & Nicholson; Geoffrey & Cave; Gillian & Nicholson; Sarah J.
  Assignee(s): LIPHA
  The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.
  
  Patent expiration dates:
  
  
  • July 14, 2019
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES
  
  
  
  • January 14, 2020
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Glucovance Consumer Information (Drugs.com)
• Glucovance Consumer Information (Wolters Kluwer)
• Glucovance Consumer Information (Cerner Multum)
• Glucovance Advanced Consumer Information (Micromedex)
• Glyburide/Metformin Consumer Information (Wolters Kluwer)
• Glyburide and metformin Consumer Information (Cerner Multum)
• Glyburide and metformin Advanced Consumer Information (Micromedex)

Nephrotic Syndrome Medications

Definition of Nephrotic Syndrome: Nephrotic syndrome is a constellation of signs and symptoms including protein in the urine (exceeding 3.5 grams per day), low blood protein levels, high cholesterol levels, and swelling. The urine may also contain fat, which is visible under the microscope.

Drugs associated with Nephrotic Syndrome

The following drugs and medications are in some way related to, or used in the treatment of Nephrotic Syndrome. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Nephrotic Syndrome

Medical Encyclopedia:

• Nephrotic syndrome

Drug List:

Aldactazide

Aristocort

Bubbli-Pred

Cellcept

Clinacort-Injection

Clinalog-Injection

Cortone-Acetate

Cytoxan

Cytoxan-Lyophilized-Oral-Injection

Deltasone

Flo-Pred

Hydeltrasol

Ken-Jec-40-Injection

Kenalog-40-Suspension

Key-Pred-Sp

Meticorten

Millipred

Millipred-Dp

Neosar

Orapred

Orapred-Odt

Pediapred-Liquid

Pred-Ject-50

Predacort-50

Predalone-50

Predate-50

Prelone-Syrup

Sterapred

Sterapred-Ds

Tac-3-Injection

Triam-Forte

Triamcot-Injection

Triamonide-40-Injection

U-Tri-Lone-Injection

Veripred-20-Solution

Olsalazine Sodium

Olsalazine Sodium may be available in the countries listed below.

Ingredient matches for Olsalazine Sodium

Olsalazine

Olsalazine Sodium (BANM, USAN) is known as Olsalazine in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Undepre

Undepre may be available in the countries listed below.

Ingredient matches for Undepre

Trazodone

Trazodone hydrochloride (a derivative of Trazodone) is reported as an ingredient of Undepre in the following countries:

• Japan

International Drug Name Search

Naftazolina

Naftazolina may be available in the countries listed below.

Ingredient matches for Naftazolina

Naphazoline

Naphazoline hydrochloride (a derivative of Naphazoline) is reported as an ingredient of Naftazolina in the following countries:

• Italy

International Drug Name Search

Zinc and Salicylic acid

Zinc and Salicylic acid may be available in the countries listed below.

Ingredient matches for Zinc and Salicylic acid

Salicylic Acid

Salicylic Acid is reported as an ingredient of Zinc and Salicylic acid in the following countries:

• Japan

Zinc Oxide

Zinc Oxide is reported as an ingredient of Zinc and Salicylic acid in the following countries:

• Japan

International Drug Name Search

Nandrolone Decanoate

Nandrolone Decanoate may be available in the countries listed below.

Ingredient matches for Nandrolone Decanoate

Nandrolone

Nandrolone Decanoate (BANM, USAN) is known as Nandrolone in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Unacid PD oral

Unacid PD oral may be available in the countries listed below.

Ingredient matches for Unacid PD oral

Sultamicillin

Sultamicillin is reported as an ingredient of Unacid PD oral in the following countries:

• Germany

Sultamicillin tosilate (a derivative of Sultamicillin) is reported as an ingredient of Unacid PD oral in the following countries:

• Germany

International Drug Name Search

Nomégestrol Winthrop

Nomégestrol Winthrop may be available in the countries listed below.

Ingredient matches for Nomégestrol Winthrop

Nomegestrol

Nomegestrol acetate (a derivative of Nomegestrol) is reported as an ingredient of Nomégestrol Winthrop in the following countries:

• France

International Drug Name Search

Seizures (Convulsions) Medications

Definition of Seizures: A seizure or convulsion can be a sudden, violent, uncontrollable contraction of a group of muscles. A seizure can also be more subtle, consisting of only a brief "loss of contact" or a few moments of what appears to be daydreaming.

Drugs associated with Seizures

The following drugs and medications are in some way related to, or used in the treatment of Seizures. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Seizures

• Seizure Prevention (30 drugs)

Learn more about Seizures (Convulsions)

Micromedex Care Notes:

• Epilepsy
• Febrile Seizure In Children
• Non-epileptic Seizures

Medical Encyclopedia:

• Convulsions
• Epilepsy
• Febrile seizures
• Seizures

Drug List:

Aminoxin

Celontin

Crinone-Gel

Depacon

Depakene

Diastat-Gel

Diastat-Acudial-Gel

Diastat-Pediatric

Diazepam-Intensol-Concentrate

Dilantin

Endometrin

First-Progesterone-Mc10

First-Progesterone-Mc5

Gabitril

Keppra

Keppra-Xr-Extended-Release-Tablets

Luminal

Menopause-Formula-Progesterone

Mysoline

Nestrex

Paradione

Peganone

Pentothal

Phenytek-Extended-Release-Capsules

Phenytoin-Sodium-Prompt

Potiga

Prochieve-Gel

Progest

Prometrium

Sabril

Solfoton

Stavzor

Tridione

Trileptal

Valium

Valrelease

Vimpat

Vitamin-B6

Zarontin

Zonegran

Sinestic Orifarm

Sinestic Orifarm may be available in the countries listed below.

Ingredient matches for Sinestic Orifarm

Budesonide

Budesonide is reported as an ingredient of Sinestic Orifarm in the following countries:

• Denmark

Formoterol

Formoterol fumarate dihydrate (a derivative of Formoterol) is reported as an ingredient of Sinestic Orifarm in the following countries:

• Denmark

International Drug Name Search

Vasotop

Vasotop may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vasotop

Amlodipine

Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Vasotop in the following countries:

• Ecuador

Nimodipine

Nimodipine is reported as an ingredient of Vasotop in the following countries:

• India


• Peru

Ramipril

Ramipril is reported as an ingredient of Vasotop in the following countries:

• Australia


• Austria


• Belgium


• Finland


• France


• Germany


• Ireland


• Italy


• Luxembourg


• Netherlands


• Portugal


• Switzerland


• United Kingdom

International Drug Name Search

Miscellaneous anxiolytics, sedatives and hypnotics

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

Anxiolytics, sedatives and hypnotics are drugs that work on the central nervous system to treat anxiety and insomnia. The main classes of drugs are benzodiazepines and barbiturates.

See also

Medical conditions associated with miscellaneous anxiolytics, sedatives and hypnotics:

• ADHD
• Allergic Reactions
• Allergic Urticaria
• Allergies
• Anxiety
• Cataplexy
• Cold Symptoms
• Conjunctivitis, Allergic
• Cough
• Depression
• Extrapyramidal Reaction
• Fibromyalgia
• Hay Fever
• Insomnia
• Interstitial Cystitis
• Irritable Bowel Syndrome
• Jet Lag
• Motion Sickness
• Narcolepsy
• Nasal Congestion
• Nausea/Vomiting
• Pain
• Panic Disorder
• Premenstrual Dysphoric Disorder
• Pruritus
• Reflex Sympathetic Dystrophy Syndrome
• Rhinorrhea
• Sedation
• Sexual Dysfunction, SSRI Induced
• Smoking Cessation
• Upper Respiratory Tract Infection
• Urticaria

Drug List:

Compoz-Nighttime-Sleep-Aid

Sominex

Unisom-Sleepmelts

Edluar

Unisom

Xyrem

Aquachloral-Supprettes-Suppositories

Children-S-Allergy

Miltown

Nytol

Silenor

Simply-Sleep

Sinequan

Sonata

Adapin

Ambien

Atarax

Benadryl-Allergy-Chewable-Tablets

Lunesta

Ambien-Cr-Extended-Release-Tablets

Benadryl

Banophen

Hyzine

Placidyl

Somnote

Unisom-Sleepgels-Maximum-Strength

Buspar

Calm-Aid

Zolpimist

Vistaril

Rozerem

40-Winks

Triaminic-Thin-Strips-Orally-Disintegrating-Strips

Nytol-Caplet

Aldex-An-Suspension

Aldex-An-Chewable-Chewable-Tablets

Aler-Dryl

Aler-Tab

Allermax

Altaryl

Aminomine

Ben-Tann-Suspension

Care-One-Sleep-Aid

Complete-Allergy-Chewable-Tablets

Dicopanol

Diphedryl

Diphen

Diphen-Cough

Diphenhist

Doxytex-Liquid

Dytan-Suspension

Dytuss-Elixir

Equaline-Sleep-Aid

Equanil

Equate-Sleep-Aid

Genahist

Hydramine

Intermezzo

Mb-Tab

Medi-Sleep

Nu-Med

Nytol-Maximum-Strength

Pediacare-Children-S-Allergy

Precedex

Q-Dryl

Q-Dryl-A-F

Quenalin

Siladryl

Siladryl-Allergy

Silphen-Cough

Sleep

Sleep-Ettes

Sleep-Ettes-D

Sleep-Aid-Tablets

Sleepinal

Sominex-Maximum-Strength-Caplet

Sunmark-Sleep-Aid

Theraflu-Multi-Symptom-Orally-Disintegrating-Strips

Twilite

Valu-Dryl

Vanspar

Diconate

Diconate may be available in the countries listed below.

Ingredient matches for Diconate

Econazole

Econazole nitrate (a derivative of Econazole) is reported as an ingredient of Diconate in the following countries:

• Bangladesh

International Drug Name Search

Hitrizin

Hitrizin may be available in the countries listed below.

Ingredient matches for Hitrizin

Cetirizine

Cetirizine is reported as an ingredient of Hitrizin in the following countries:

• Turkey

International Drug Name Search